A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV
Rotavirus Vaccine
Infections, Rotavirus
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014